Richard A. Paulson Sells 2,115 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) CEO Richard A. Paulson sold 2,115 shares of the stock in a transaction on Friday, July 8th. The stock was sold at an average price of $5.18, for a total transaction of $10,955.70. Following the completion of the sale, the chief executive officer now owns 628,791 shares in the company, valued at approximately $3,257,137.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
KPTI stock traded down $0.37 during midday trading on Monday, hitting $4.88. 1,835,223 shares of the stock traded hands, compared to its average volume of 3,104,530. The firm has a market cap of $387.56 million, a P/E ratio of -3.32 and a beta of 0.05. The stock’s fifty day simple moving average is $5.46 and its 200-day simple moving average is $7.14. Karyopharm Therapeutics Inc. has a 1-year low of $4.02 and a 1-year high of $14.73.
Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.10. The firm had revenue of $47.67 million for the quarter, compared to analyst estimates of $34.78 million. During the same quarter in the prior year, the business posted ($0.77) EPS. Sell-side analysts anticipate that Karyopharm Therapeutics Inc. will post -2.06 EPS for the current year.
KPTI has been the topic of a number of research reports. StockNews.com initiated coverage on shares of Karyopharm Therapeutics in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. HC Wainwright cut their price objective on shares of Karyopharm Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, March 18th. Finally, Canaccord Genuity Group cut their price objective on shares of Karyopharm Therapeutics from $20.00 to $10.00 in a research note on Monday, April 11th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $11.57.
A number of hedge funds have recently added to or reduced their stakes in KPTI. Bank of America Corp DE lifted its holdings in Karyopharm Therapeutics by 338.0% during the first quarter. Bank of America Corp DE now owns 1,116,230 shares of the company’s stock valued at $8,227,000 after purchasing an additional 861,362 shares in the last quarter. Walleye Capital LLC lifted its holdings in Karyopharm Therapeutics by 439.4% during the first quarter. Walleye Capital LLC now owns 83,078 shares of the company’s stock valued at $612,000 after purchasing an additional 67,675 shares in the last quarter. Rice Hall James & Associates LLC lifted its holdings in Karyopharm Therapeutics by 5.3% during the first quarter. Rice Hall James & Associates LLC now owns 1,344,929 shares of the company’s stock valued at $9,912,000 after purchasing an additional 68,295 shares in the last quarter. Walleye Trading LLC lifted its holdings in Karyopharm Therapeutics by 728.1% during the first quarter. Walleye Trading LLC now owns 26,482 shares of the company’s stock valued at $195,000 after purchasing an additional 23,284 shares in the last quarter. Finally, Quantbot Technologies LP lifted its holdings in Karyopharm Therapeutics by 773.8% during the first quarter. Quantbot Technologies LP now owns 53,300 shares of the company’s stock valued at $392,000 after purchasing an additional 47,200 shares in the last quarter. Institutional investors own 67.75% of the company’s stock.
Karyopharm Therapeutics Company Profile (Get Rating)
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider Karyopharm Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Karyopharm Therapeutics wasn’t on the list.
While Karyopharm Therapeutics currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.